BioPharma Resources

Drugs by condition

Drugs approved for epilepsy and seizures

Brand-name prescription drugs and biologics whose FDA label lists epilepsy and seizures as an approved use. Matched on the label phrases: "seizures", "epilepsy".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

77

Still marketed, NDA or BLA

Drug classes

8

Novel drugs

27

New molecular entities and new biologics

In development

14

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for epilepsy and seizures.

  • Subvenite (Lamotrigine) · Owp Pharms Sep 16, 2025
  • Motpoly Xr (Lacosamide) · Aucta May 4, 2023
  • Sezaby (Phenobarbital Sodium) · Sparc Priority reviewOrphanNov 17, 2022
  • Zonisade (Zonisamide) · Azurity Jul 15, 2022
  • Ztalmy (Ganaxolone) · Immedica Pharma NovelPriority reviewOrphanMar 18, 2022

All approved drugs for epilepsy and seizures, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 512 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Anti-epileptic Agent (17)

  • Sabril Vigabatrin · Lundbeck Pharms LLC · 2009
  • Zonegran Zonisamide · Advanz Pharma · 2000
  • Trileptal Oxcarbazepine · Novartis · 2000
  • Lamictal Lamotrigine · Glaxosmithkline LLC · 1994
  • Felbatol Felbamate · Mylan Speciality Lp · 1993
  • Zarontin Ethosuximide · Parke Davis · 1960
  • Celontin Methsuximide · Parke Davis · 1957
  • Mysoline Primidone · Valeant · 1954
  • Subvenite Lamotrigine · Owp Pharms · 2025
  • Zonisade Zonisamide · Azurity · 2022
  • Oxtellar Xr Oxcarbazepine · Supernus Pharms · 2012
  • Sabril Vigabatrin · Lundbeck Pharms LLC · 2009
  • Lamictal Xr Lamotrigine · Glaxosmithkline LLC · 2009
  • Lamictal Odt Lamotrigine · Glaxosmithkline LLC · 2009
  • Trileptal Oxcarbazepine · Novartis · 2001
  • Lamictal Cd Lamotrigine · Glaxosmithkline LLC · 1998
  • Dilantin-125 Phenytoin · Viatris · 1953

Benzodiazepine (7)

  • Onfi Clobazam · Lundbeck Pharms LLC · 2011
  • Klonopin Clonazepam · Cheplapharm · 1975
  • Valtoco Diazepam · Neurelis INC · 2020
  • Nayzilam Midazolam · Ucb INC · 2019
  • Sympazan Clobazam · Cosette · 2018
  • Onfi Clobazam · Lundbeck Pharms LLC · 2012
  • Diastat Acudial Diazepam · Bausch · 1997

Mood Stabilizer (5)

  • Tegretol Carbamazepine · Novartis · 1968
  • Equetro Carbamazepine · Validus Pharms · 2004
  • Carbatrol Carbamazepine · Takeda Pharms USA · 1997
  • Tegretol-Xr Carbamazepine · Novartis · 1996
  • Tegretol Carbamazepine · Novartis · 1987

Noncompetitive AMPA Glutamate Receptor Antagonist (2)

  • Fycompa Perampanel · Catalyst Pharms · 2012
  • Fycompa Perampanel · Catalyst Pharms · 2016

Kinase Inhibitor (2)

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator (1)

  • Ztalmy Ganaxolone · Immedica Pharma · 2022

Radioactive Diagnostic Agent (1)

Class not listed in FDA's data (42)

Drugs in development for epilepsy and seizures

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • AzetukalnerXEN1101Phase 39 trials

    Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder

  • BHV-7000Phase 36 trials

    Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder

  • RAP-219Phase 35 trials

    Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure

  • NRTX-1001GABA-secreting interneuronsPhase 32 trials

    Neurona Therapeutics · Epilepsy, Temporal Lobe, Mesial Temporal Lobe Epilepsy

  • PBOPhase 32 trials

    SK Life Science, Inc. · Primary Generalized Epilepsy, Treatment Resistant Depression

  • Staccato alprazolamUCB7538Phase 32 trials

    UCB · Stereotypical Prolonged Seizures

  • Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy

  • JZP926Phase 31 trial

    Jazz Pharmaceuticals · Juvenile Myoclonic Epilepsy

  • SPN-817BIS-001ER, Huperzine APhase 24 trials

    Supernus Pharmaceuticals, Inc. · Focal Onset Seizures, Focal Impaired Awareness Seizures, Epilepsy

  • BMB-101Phase 22 trials

    Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome

  • ABS-1230Phase 21 trial

    Actio Biosciences, Inc. · KCNT1-Related Epilepsy

  • AV078Phase 21 trial

    Aeovian Pharmaceuticals, Inc. · Tuberous Sclerosis Complex, Epilepsy

  • CB03-154Phase 21 trial

    Shanghai Zhimeng Biopharma, Inc. · Focal Epilepsy

  • NPT 2042Phase 21 trial

    NeuroPro Therapeutics, Inc. · Epilepsy, Generalized, Epilepsy, Absence

2 discontinued brand-name drugs whose label still names it

More on epilepsy and seizures: recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.